中国临床保健杂志2018，Vol.21Issue(2)：242-245,4.DOI:10.3969/J.issn.1672-6790.2018.02.027
表皮生长因子受体基因突变状态对晚期肺腺癌一线化疗效果的影响
The influence of EGFR mutation status on first-line chemotherapy efficacy in advanced lung adenocarcinoma
张萍 1武晓楠 1聂鑫 1李旭 1艾斌 1李琳1
作者信息
- 1. 北京医院 国家老年医学中心肿瘤内科,北京100730
- 折叠
摘要
Abstract
Objective To explore the impact of EGFR gene status to the therapeutic effect of first-line chemo-therapy in patients with advanced lung adenocarcinoma.Methods We had collected the clinical data of patients with advanced lung adenocarcinoma and treated with first-line combined chemotherapy based on platinum.We had analyzed the relationship of EGFR gene status with chemotherapeutic effect and progression free survival time.Results Of all the 271 patients who received first-line chemotherapy with platinum-based drugs,192 cases(70.8%)with wild EGFR gene,79 cases(29.2%)with mutation EGFR gene.The objective response rates of wild and mutation EGFR were 30.2% and 35.4% respectively(P =0.524),disease control rates were 71.9% and 81.0%,respectively(P =0.292).The comparison of the RR and DCR of first-line chemotherapy in patients with EGFR mutation and wild lung adenocarcinoma was of no significant difference.The median progression free survival time of EGFR wild type was 4.6 months and that of EGFR mutation was 5.3 months,and there was no significant difference between these two types kinds of patients(P=0.299).Conclusion The impact of EGFR gene mutation to the short-term effect and progression free survival of first-line chemotherapy is not significant.关键词
肺肿瘤/受体,表皮生长因子/DNA突变分析/药物疗法Key words
Lung neoplasms/Receptor,epidermal growth factor/DNA mutational analysis/Drug therapy分类
医药卫生引用本文复制引用
张萍,武晓楠,聂鑫,李旭,艾斌,李琳..表皮生长因子受体基因突变状态对晚期肺腺癌一线化疗效果的影响[J].中国临床保健杂志,2018,21(2):242-245,4.
